Innovative Health, LLC appears in FDA device records as the applicant for reprocessed cardiovascular devices under product code NMK, regulation number 870.1390, device class II. The supplied filings show one linked 510(k) record, K262917, decided October 19, 2026 as substantially equivalent, with a decision date and submission date of August 20, 2026. A separate 2020 clearance, K192998, documents the same device family and describes how the reprocessing is bounded. The company's own published materials describe its device scope and its stated rationale for single-use device reprocessing in cardiology. [1][2][3][4]
Documented products and device construction
The Reprocessed BRK Transseptal Needle is described in the company's instructions for use as consisting of a luminal stainless steel needle and a solid stainless steel stylet, with the distal section of the needle curved for positioning. The same document covers the Reprocessed BRK and BRK-1 Transseptal Needle and labels the product a reprocessed device for single use, restricted by federal law to sale by or on the order of a physician. The instructions state that the product and its packaging have been sterilized with ethylene oxide and include a California Proposition 65 exposure notice for EO. [2]
The company's available-devices page lists mapping catheters among the devices it addresses, describing them as the most difficult devices to reprocess because many have micro-lumens that present an additional challenge to clean and inspect. That characterization is the publisher's own description of device difficulty, not an independently verified performance measure. [4]
Filing history and reprocessing limits
FDA records for K262917 name Innovative Health, LLC as applicant for the Reprocessed BRK Transseptal Needle, product code NMK, advisory committee CV, clearance type Traditional, with a third-party review flag of N and a decision of substantially equivalent on October 19, 2026. The submission was received August 20, 2026, and the record notes a summary rather than a statement. [1]
An earlier clearance, K192998, dated July 22, 2020, covers the same trade name and regulation, and the accompanying summary states that the device is reprocessed no more than one time, that each device is serialized and tracked, and that devices reaching the maximum number of reprocessing cycles are rejected from further reprocessing. The summary states that reprocessing is performed only by Innovative Health, LLC and that the company restricts its reprocessing to exclude devices previously reprocessed by other reprocessors. The FDA database entry for K192998 records a substantially equivalent decision, a Traditional review type, no third-party review, and no combination product status. [3][6]
Company statements and scope of the record
The company’s own site describes development of reprocessing technologies for hospitals. Its page also refers to a December 2015 Journal of Medical Devices publication. Those company statements describe its published research and development positioning; they do not independently establish clinical outcomes or cost savings. [5]
The available-devices page states that the company received its first clearance in March 2016 and had received 38 clearances by the spring of 2021, a figure the publisher compares with clearances received by other EP reprocessors. The supplied collection, as of November 20, 2026, contains one linked 510(k) record with a substantially equivalent decision, and the smaller record sample likewise contains one such record; these counts describe the supplied filings only and are not total company sales, total portfolio or safety performance. No parent, brand or ownership relationship is verified in the sources, and the Scottsdale, Arizona address appears in FDA and company documents as a filing and contact address. [1][4]
